Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 10/20 | 0.56 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130536 | 0.97 | KISS1R (0.56) | KISS1RMAGI3IL23RSIRT5PRMT1 | |
| SCHEMBL30130564 | 0.97 | KISS1R (0.56) | KISS1RMAGI3IL23RSIRT5PRMT1 | |
| SCHEMBL30148460 | 0.97 | KISS1R (0.54) | KISS1RMAGI3IL23RSIRT5PRMT1 | |
| SCHEMBL29800092 | 0.97 | KISS1R (0.54) | KISS1RMAGI3IL23RSIRT5PRMT1 | |
| SCHEMBL31110538 | 0.97 | KISS1R (0.54) | KISS1RMAGI3IL23RSIRT5PRMT1 | |
| SCHEMBL30305295 | 0.97 | KISS1R (0.54) | KISS1RMAGI3IL23RSIRT5PRMT1 | |
| SCHEMBL30302874 | 0.97 | KISS1R (0.54) | KISS1RMAGI3IL23RSIRT5PRMT1 | |
| SCHEMBL30148455 | 0.97 | KISS1R (0.56) | KISS1RMAGI3IL23RSIRT5PRMT1 | |
| SCHEMBL30093096 | 0.97 | KISS1R (0.56) | KISS1RMAGI3IL23RSIRT5PRMT1 | |
| SCHEMBL29732610 | 0.97 | KISS1R (0.54) | KISS1RMAGI3IL23RSIRT5PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4401752-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | Peptilogics, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2023044423-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. (US) | 2023-03-23 | — | — | WO | claimed |
| US-20250195611-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20240252586-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | PEPTILOGICS, INC. | 2024-04-11 | — | — | US | disclosed |
| US-20230106943-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | PEPTILOGICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2023044487-A1 | TREATMENT OF LUNG DISEASE OR INJURY USING ENGINEERED ANTIMICROBIAL PEPTIDES | PEPTILOGICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195611-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | VIP, SPPL2B, HM13 | KISS1R 3745/4885MAGI3 2045/4885IL23R 610/4885 |
| US-20240115654-A1 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | IAPP, VIP, NGLY1 | KISS1R 3225/4885MAGI3 4082/4885IL23R 1571/4885 |
| US-20230106943-A1 | ENGINEERED ANTIMICROBIAL PEPTIDES AND USAGE THEREOF | VIP, SPPL2B, HM13 | KISS1R 3745/4885MAGI3 2045/4885IL23R 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.